Pfizer CEO Albert Bourla said Sunday that the company is planning to submit the data it compiled from COVID-19 vaccine trials for children between the ages of 5 and 11 to the Food and Drug Administration quite soon.
"It's a question of days, not weeks," he told ABC News' George Stephanopoulos on Sunday's edition of This Week.
Last week, Pfizer revealed that the vaccine it developed in tandem with BioNTech was safe and effective within the age group even with a smaller dose than the one that's been approved for ages 12 and up.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Once the FDA can review that information, the vaccine will be on track to become available for younger children, which will likely go a long way toward solidifying pandemic-related education policies throughout the U.S.
Create an account with the same email registered to your subscription to unlock access.